Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 24, Issue 6, 2014, Pages 656-662

  Jorgensen M E ^a   Torp Pedersen, C ^b   Finer, N ^c   Caterson, I ^d   James, W P T ^e   Legler, U F ^f   Andersson, C ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f Special Vocational College for Handicapped Persons   (Germany)

Author keywords

Bilirubin; Cardiovascular disease; SCOUT

Indexed keywords

BILIRUBIN; PLACEBO; SIBUTRAMINE;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; WEIGHT REDUCTION; AGED; BLOOD; BODY MASS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COHORT ANALYSIS; DOUBLE BLIND PROCEDURE; HEART ARREST; LIFESTYLE; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; OVERWEIGHT; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STROKE; UPREGULATION;

AGED; BILIRUBIN; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEART ARREST; HUMANS; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; OBESITY; OVERWEIGHT; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; UP-REGULATION; WEIGHT LOSS;

EID: 84901507599     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2013.12.009     Document Type: Article

References (20)

1. Lin J.P., Vitek L., Schwertner H.A. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010, 56(10):1535-1543.
2. Schwertner H.A., Jackson W.G., Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994, 40(1):18-23.
3. Tanaka M., Fukui M., Tomiyasu K., Akabame S., Nakano K., Hasegawa G., et al. Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis 2009, 206(1):287-291.
4. Kimm H., Yun J.E., Jo J., Jee S.H. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 2009, 40(11):3422-3427.
5. Rantner B., Kollerits B., Anderwald-Stadler M., Klein-Weigel P., Gruber I., Gehringer A., et al. Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. Clin Chem 2008, 54(5):851-857.
6. Breimer L.H., Wannamethee G., Ebrahim S., Shaper A.G. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995, 41(10):1504-1508.
7. Djousse L., Levy D., Cupples L.A., Evans J.C., D'Agostino R.B., Ellison R.C. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001, 87(10):1196-1200. A4, 7.
8. Perlstein T.S., Pande R.L., Creager M.A., Weuve J., Beckman J.A. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med 2008, 121(9):781-788 e1.
9. Horsfall L.J., Nazareth I., Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation 2012, 126(22):2556-2564.
10. James W.P., Caterson I.D., Coutinho W., Finer N., Van Gaal L.F., Maggioni A.P., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010, 363(10):905-917.
11. Andersson C., Weeke P., Fosbol E.L., Brendorp B., Kober L., Coutinho W., et al. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the sibutramine cardiovascular outcome trial. Metabolism 2009, 58(8):1109-1115.
12. ® 2010, [Advisory committee briefing document], Available from:. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM225573.pdf.
13. Schwertner H.A., Fischer J.R. Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease. Atherosclerosis 2000, 150(2):381-387.
14. Vitek L., Jirsa M., Brodanova M., Kalab M., Marecek Z., Danzig V., et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002, 160(2):449-456.
15. Ong K.L., Wu B.J., Cheung B.M., Barter P.J., Rye K.A. Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008. Atherosclerosis 2011, 219(2):728-733.
16. McDonagh A.F. The biliverdin-bilirubin antioxidant cycle of cellular protection: missing a wheel?. Free Radic Biol Med 2010, 49(5):814-820.
17. Mishra P., Samanta L. Oxidative stress and heart failure in altered thyroid states. Sci World J 2012, 2012:741861.
18. Schwertner H.A., Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008, 198(1):1-11.
19. Bulmer A.C., Blanchfield J.T., Toth I., Fassett R.G., Coombes J.S. Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 2008, 199(2):390-396.
20. Lin J.P., O'Donnell C.J., Schwaiger J.P., Cupples L.A., Lingenhel A., Hunt S.C., et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006, 114(14):1476-1481.